TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 37074571
Drug: Surufatinib 300
Normalized name: Surufatinib
DrugBank: Surufatinib (DB15106)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surufatinib 300 mg QD (pNET cohort)
Study: 37074571
Drug: Surufatinib 300
Normalized name: Surufatinib
DrugBank: Surufatinib (DB15106)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surufatinib 300 mg QD (epNET cohort)
Study: 37074571
Drug: Surufatinib 300
Normalized name: Surufatinib
DrugBank: Surufatinib (DB15106)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surufatinib 300 mg QD (both cohorts)
Study: 37074698
Drug: Brief Interpersonal
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Brief Interpersonal Therapy (IPT)
Study: 37074775
Drug: Standard of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of care (SOC) for PrEP choice (oral or CAB-LA)
Study: 37075129
Drug: 20 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 μg of H1ssF once
Study: 37075254
Drug: 177 Lu-DOTA-EB-TATE
Normalized name: Lu-DOTA-TATE
DrugBank: Lutetium Lu 177 dotatate (DB13985)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 177 Lu-DOTA-EB-TATE without amino acid infusion
Study: 37075254
Drug: 177 Lu-DOTA-EB-TATE
Normalized name: Lu-DOTA-TATE
DrugBank: Lutetium Lu 177 dotatate (DB13985)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 177 Lu-DOTA-EB-TATE with amino acid infusion
Study: 37075255
Drug: Weekly dose-dense
Normalized name: selinexor
DrugBank: Selinexor (DB11942)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Weekly dose-dense chemotherapy
Study: 37075255
Drug: Standard three-weekly
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard three-weekly carboplatin-paclitaxel regimens
Study: 37075617
Drug: Mobocertinib 160
Normalized name: Mobocertinib
DrugBank: Mobocertinib (DB16390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mobocertinib 160 mg QD
Study: 37075617
Drug: Real-world treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Real-world treatments (EGFR TKI 20%, immuno-oncology therapy 40%, chemotherapy 40%)
Study: 37075781
Drug: Pembrolizumab 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pembrolizumab 200 mg plus gemcitabine and cisplatin
Study: 37075965
Drug: 8-week self-administered
Normalized name: milnacipran
DrugBank: Milnacipran (DB04896)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 8-week self-administered dyadic intervention (ReStoreD) consisting of activities completed individually and as a couple.
Study: 37076132
Drug: Risk-based follow-up
Normalized name: Q-Up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risk-based follow-up strategies for G-(MA)NEC
Study: 37076159
Drug: Flexible care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flexible care with subcutaneous atezolizumab (1875 mg; Day 1 of each 21-day cycle) administered in the hospital, followed by 13 cycles at home by a healthcare professional
Study: 37076252
Drug: Bupivacaine implant
Normalized name: bupivacaine Drug Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine implant (300 mg, three 100 mg implants)
Study: 37076252
Drug: Placebo (three
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (three collagen implants)
Study: 37076424
Drug: Beta-lactam therapeutic
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-lactam therapeutic drug monitoring (BL TDM)
Study: 37076476
Drug: Conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapy (metformin with or without insulin)
Study: 37077305
Drug: Ophthalmic DMPC-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ophthalmic DMPC-based nanoemulsion (Nanodrop®)
Study: 37077916
Drug: Golidocitinib (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Golidocitinib (5 - 150 mg single dose; 25 - 100 mg once daily for 14 days)
Study: 37077916
Drug: Golidocitinib (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Golidocitinib (50 mg) under fed conditions
Study: 37077916
Drug: Golidocitinib (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Golidocitinib (25 - 150 mg single dose)
Study: 37077916
Drug: Golidocitinib (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Golidocitinib (50 mg)
Study: 37077927
Drug: Biofilm disrupting
Normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Biofilm disrupting acne cream 2x
Study: 37077927
Drug: Biofilm disrupting
Normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Biofilm disrupting acne cream 1x
Study: 37077927
Drug: Biofilm disrupting
Normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Biofilm disrupting acne cream without salicylic acid
Study: 37078004
Drug: Simultaneous integrated
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Simultaneous integrated boost (SIB) with concurrent chemotherapy
Study: 37078188
Drug: Active Control
Normalized name: Accu-Chek Active Control Solution
DrugBank: Pyrithione (DB06815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active Control (CTRL) therapy
Study: 37078412
Drug: Entospletinib 400
Normalized name: Entospletinib
DrugBank: Entospletinib (DB12121)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Entospletinib 400 mg twice daily with decitabine 20 mg/m²
Study: 37078706
Drug: Orelabrutinib 150
Normalized name: Orelabrutinib
DrugBank: Orelabrutinib (DB16272)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orelabrutinib 150 mg once daily
Study: 37078706
Drug: Orelabrutinib 100
Normalized name: acalabrutinib 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orelabrutinib 100 mg twice daily
Study: 37078706
Drug: Orelabrutinib (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orelabrutinib (both doses)
Study: 37078771
Drug: Piperacillin-tazobactam (3.375
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piperacillin-tazobactam (3.375 or 4 g intravenously)
Study: 37078771
Drug: Cefoxitin (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefoxitin (2 g intravenously; standard care)
Study: 37078969
Drug: Goal-focused Emotion-regulation
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Goal-focused Emotion-regulation Therapy (GET)
Study: 37079305
Drug: Daily-life fall
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily-life fall rates
Study: 37079305
Drug: Other daily-life
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other daily-life fall-related metrics
Study: 37079324
Drug: Stereotactic radiosurgery
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stereotactic radiosurgery (SRS) with a single dose of 16 or 18 Gy to involved vertebral levels
Study: 37079363
Drug: Mobile Acceptance
Normalized name: Chamaemelum nobile extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mobile Acceptance and Commitment Therapy (ACT) intervention
Study: 37079518
Drug: Patients with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients with small LLD (indicating better prognosis and better anti-VEGF treatment response).
Study: 37079851
Drug: Content control
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Content control with nonimmersive tablet computer (Tablet Blu)
Study: 37079894
Drug: Rifabutin triple
Normalized name: Rifabutin
DrugBank: Rifabutin (DB00615)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rifabutin triple therapy (14-day esomeprazole 20 mg, amoxicillin 1.0 g, rifabutin 150 mg twice a day)
Study: 37079894
Drug: Bismuth quadruple
Normalized name: bismuth
DrugBank: Bismuth cation (DB14572)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bismuth quadruple therapy (esomeprazole 20 mg, bismuth 220 mg twice a day, metronidazole 400 mg, tetracycline 500 mg 4 times a day)
Study: 37080223
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemotherapy (carboplatin and paclitaxel) after standard cisplatin-based chemoradiotherapy
Study: 37080223
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemotherapy (carboplatin and paclitaxel)
Study: 37080462
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg PP + CC
Study: 37080462
Drug: PP (doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: PP (doses ≤150 mg)
Study: 37080829
Drug: Half-dose MVC-COV1901
Normalized name: MVC-COV1901
DrugBank: MVC-COV1901 (DB15854)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Half-dose MVC-COV1901
Study: 37080829
Drug: Full-dose MVC-COV1901
Normalized name: MVC-COV1901
DrugBank: MVC-COV1901 (DB15854)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Full-dose MVC-COV1901
Study: 37080829
Drug: Half-dose mRNA-1273
Normalized name: MRNA-1273 SARS-COV-2
DrugBank: Moderna COVID-19 Vaccine (DB15654)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Half-dose mRNA-1273
Study: 37080942
Drug: E7130 administered
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: E7130 administered intravenously at 480 μg/m (Q3W)
Study: 37080942
Drug: E7130 administered
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: E7130 administered intravenously at 480 μg/m (Q2W)
Study: 37081029
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil and evening primrose oil (EPO) supplementation (2 gel capsules of fish oil and 3 gel capsules of EPO for 12 weeks)
Study: 37081029
Drug: Mineral oil
Normalized name: Mineral Oil
DrugBank: Mineral oil (DB11057)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mineral oil (placebo, 5 gel capsules of 1g for 12 weeks)
Study: 37081046
Drug: Tocilizumab/infliximab with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tocilizumab/infliximab with standard treatment
Study: 37081046
Drug: Tocilizumab with
Normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Tocilizumab with standard treatment
Study: 37081406
Drug: Intensive Neurophysiological
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive Neurophysiological Rehabilitation System (INRS) treatment
Study: 37081406
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (waiting list for 4 weeks, then INRS treatment)
Study: 37081406
Drug: INRS treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: INRS treatment
Study: 37081426
Drug: Intravenous Lutetium-177
Normalized name: Lutetium-177
DrugBank: Lutetium Lu-177 (DB13982)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous Lutetium-177 PSMA Radioligand Therapy (RLT) followed by one fraction of HDR brachytherapy
Study: 37081426
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose rate (HDR) brachytherapy in two fractions (standard of care salvage treatment)
Study: 37081534
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Suubi intervention components
Study: 37081617
Drug: Guideline-recommended treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guideline-recommended treatment (ACE inhibitors, ARBs)
Study: 37081722
Drug: Pyrotinib (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pyrotinib (400 mg)
Study: 37081722
Drug: Pyrotinib plus
Normalized name: Pyrotinib
DrugBank: Pyrotinib (DB14993)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pyrotinib plus docetaxel (60 mg)
Study: 37082098
Drug: Cemiplimab 350
Normalized name: CEMIPLIMAB
DrugBank: Cemiplimab (DB14707)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Cemiplimab 350 mg every 3 weeks (Q3W)
Study: 37082098
Drug: Chemotherapy (platinum-doublet)
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (platinum-doublet)
Study: 38272571
Drug: Intravenous nerinetide
Normalized name: Nerinetide
DrugBank: Nerinetide (DB12595)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous nerinetide
Study: 37083300
Drug: Non-BMX treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-BMX treatments
Study: 37083360
Drug: Novel kit
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Novel kit formulation targeting fibroblast activation protein (FAP)
Study: 37083461
Drug: Mixed nuts
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mixed nuts (42g daily)
Study: 37083461
Drug: Potato chips
Approvals — FDA: no, EMA: no, PMDA: no
Description: Potato chips (46g daily)
Study: 37083664
Drug: Esketamine (0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esketamine (0.25 mg/kg intravenous injection)
Study: 37084261
Drug: Intrathecal oxytocin,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal oxytocin, 100 µg
Study: 37084342
Drug: Elafibranor 120
Normalized name: elafibranor
DrugBank: Elafibranor (DB05187)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Elafibranor 120 mg daily for 12 weeks
Study: 37084342
Drug: Elafibranor 80
Normalized name: elafibranor 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Elafibranor 80 mg daily for 12 weeks
Study: 37084383
Drug: Lower dose
Normalized name: flowers
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lower dose total body irradiation (200 cGy)
Study: 37084401
Drug: Conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapy (active vitamin D and phosphate)
Study: 37084590
Drug: Low-fat, vegan
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-fat, vegan diet including cooked soybeans (1/2 cup [86 g]/day) for 12 weeks
Study: 37084748
Drug: Proton therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proton therapy (54 Gy with a 0.5 cm clinical target volume margin) combined with limited surgery
Study: 37084803
Drug: AGuIX®-based radiation
Approvals — FDA: no, EMA: no, PMDA: no
Description: AGuIX®-based radiation treatments
Study: 37085287
Drug: Ropivacaine 150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine 150 mg followed by boluses of 40 mg every 6 hours and infusion of 2 mg/hour
Study: 37085287
Drug: Weight-based ropivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weight-based ropivacaine dosing
Study: 37085880
Drug: Anticholinergic bladder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anticholinergic bladder therapy (tolterodine 2 mg ER)
Study: 37085880
Drug: Beta-3 adrenergic
Normalized name: Product containing beta-3 adrenergic receptor agonist (product)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-3 adrenergic agonist bladder therapy (mirabegron 25 mg ER)
Study: 37085899
Drug: Meals delivered
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meals delivered daily to participants' homes by a volunteer or paid driver who socializes with the client
Study: 37086054
Drug: Cognitive behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavioral therapy for insomnia (CBTI)
Study: 37086083
Drug: 24-hour ambulatory
Approvals — FDA: no, EMA: no, PMDA: no
Description: 24-hour ambulatory blood pressure monitoring (ABPM) in CIS patients without antihypertensives
Study: 37086340
Drug: DMT fumarate
Normalized name: fumarate
DrugBank: Dimethyltryptamine (DB01488)
Approvals — FDA: no, EMA: no, PMDA: no
Description: DMT fumarate (SPL026) administered via a two-phase intravenous (IV) infusion, escalating doses of 9-21.5 mg (DMT freebase) over a 10-min infusion.
Study: 37086595
Drug: LEN+PEMBRO (Lenvatinib
Approvals — FDA: no, EMA: no, PMDA: no
Description: LEN+PEMBRO (Lenvatinib 20 mg/day + Pembrolizumab 200 mg Q3W)
Study: 37086595
Drug: TPC (Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: TPC (Treatment of Physician's Choice, doxorubicin 60 mg/m2)
Study: 37086745
Drug: Trastuzumab deruxtecan
Normalized name: Trastuzumab deruxtecan
DrugBank: Trastuzumab deruxtecan (DB14962)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Trastuzumab deruxtecan (5.4 mg/kg intravenously once every 3 weeks)
Study: 37086745
Drug: Treatment of
Normalized name: DRUGS FOR TREATMENT OF LEPRA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment of physician's choice (capecitabine 1250 mg/m2)
Study: 37086916
Drug: Minimal intervention
Normalized name: Centipeda minima whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Minimal intervention including a Fitbit linked with clinic's patient portal and EHR with weekly feedback
Study: 37087399
Drug: Axitinib modifications
Normalized name: Axitinib
DrugBank: Axitinib (DB06626)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Axitinib modifications (dose reduction or treatment interruption)
Study: 37087459
Drug: Weekly Abatacept
Normalized name: Abatacept
DrugBank: Abatacept (DB01281)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Weekly Abatacept + Methotrexate
Study: 37087459
Drug: Abatacept Monotherapy
Normalized name: Abatacept
DrugBank: Abatacept (DB01281)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Abatacept Monotherapy
Study: 37087950
Drug: ide-cel treatment
Normalized name: IDE-CEL
DrugBank: Idecabtagene vicleucel (DB16665)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ide-cel treatment
Study: 37088275
Drug: Continuous glucose
Normalized name: sub-q infusion pump w/continuous glucose monitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous glucose monitoring (Dexcom G6 Pro) for 10 days starting at the 50-g glucose challenge test.
Study: 37088447
Drug: Surgery (PPV,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgery (PPV, subretinal tPA [maximum, 0.5 ml/50 μg], and 20% sulfur hexafluoride)
Study: 37088447
Drug: Pneumatic displacement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pneumatic displacement (PD) with tPA and VEGF inhibitor
Study: 37088458
Drug: Pegbelfermin (10,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pegbelfermin (10, 20, or 40 mg)
Study: 37088458
Drug: Pegbelfermin (10,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pegbelfermin (10, 20, or 40 mg) injected subcutaneously once weekly for 48 weeks
Study: 37088458
Drug: Placebo injected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo injected subcutaneously once weekly for 48 weeks
Study: 37088458
Drug: Pegbelfermin (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pegbelfermin (20 or 40 mg)
Study: 37088458
Drug: 40-mg pegbelfermin
Normalized name: Pegbelfermin
DrugBank: Pegbelfermin (DB15365)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40-mg pegbelfermin
Study: 37088866
Drug: Restorex penile
Approvals — FDA: no, EMA: no, PMDA: no
Description: Restorex penile traction therapy (RxPTT)
Study: 37088866
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment (Tx)
Study: 37088866
Drug: Crossover to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Crossover to no treatment after initial treatment (Group 3)
Study: 37088964
Drug: 4CMenB and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4CMenB and MenACWY vaccines
Study: 37089721
Drug: Systemic and
Normalized name: Estradiol and Levonorgestrel Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic and topical medications
Study: 37090089
Drug: Lipid-lowering therapies
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lipid-lowering therapies (LLTs)
Study: 37093072
Drug: IMMUNOREACT 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: IMMUNOREACT 1 cohort (therapy naive)
Study: 37093072
Drug: IMMUNOREACT 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: IMMUNOREACT 2 cohort (patients who had neoadjuvant therapy)
Study: 37093160
Drug: Oral Cannabidiol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Cannabidiol
Study: 37093466
Drug: SYHA1402 25
Approvals — FDA: no, EMA: no, PMDA: no
Description: SYHA1402 25 mg
Study: 37093466
Drug: SYHA1402 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: SYHA1402 50 mg
Study: 37093466
Drug: SYHA1402 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: SYHA1402 100 mg
Study: 37093466
Drug: SYHA1402 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: SYHA1402 200 mg
Study: 37093466
Drug: SYHA1402 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: SYHA1402 400 mg
Study: 37093466
Drug: SYHA1402 800
Approvals — FDA: no, EMA: no, PMDA: no
Description: SYHA1402 800 mg
Study: 37093466
Drug: SYHA1402 (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: SYHA1402 (all doses)
Study: 37093466
Drug: SYHA1402 (25-100
Approvals — FDA: no, EMA: no, PMDA: no
Description: SYHA1402 (25-100 mg)
Study: 37093572
Drug: Transvaginal pudendal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transvaginal pudendal nerve block (9 mL 0.25% bupivacaine and 1 mL 40 mg/mL triamcinolone)
Study: 37093572
Drug: Sham injection
Normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham injection (10 mL normal saline)
Study: 37093833
Drug: Hormone monotherapy
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hormone monotherapy
Study: 37093892
Drug: Neutralizing antibodies
Normalized name: DentiCare Neutral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neutralizing antibodies (nAbs) from plasma samples of SFV-infected individuals
Study: 37093892
Drug: Neutralizing antibodies
Normalized name: DentiCare Neutral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neutralizing antibodies (nAbs)
Study: 37094349
Drug: Cognitive Behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioral Therapy (CBT) and Cash transfer together
Study: 37094596
Drug: Chemotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy with rituximab
Study: 37094668
Drug: Ticagrelor monotherapy
Normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ticagrelor monotherapy after 3-month dual antiplatelet therapy
Study: 37094668
Drug: Ticagrelor plus
Normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ticagrelor plus aspirin after 3-month dual antiplatelet therapy
Study: 37094892
Drug: Manual therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manual therapy combined with therapeutic exercise for 10 weeks (two visits per week)
Study: 37094943
Drug: 0.6% Lugol's
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.6% Lugol's solution
Study: 37094943
Drug: 1.2% Lugol's
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.2% Lugol's solution
Study: 37094968
Drug: Patient blood
Normalized name: dragon's blood extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient blood management program (high-dose iron supplements before and after surgery)